Program
RC28-E protein
Also written as “RC28-E”, “RC28-E injection” and “RC-28E”.
Its studies are mostly in Macular Edema · Macular Degeneration · Diabetic Retinopathy, led by RemeGen.
Furthest: phase 3, since Jan 10, 20235 company-led studies, 3 open or runningNext primary completion: Dec 1, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| RemeGen | 53 open or running | phase 3since Jan 10, 2023 | Dec 9, 2018 | Dec 1, 2028phase 3 · NCT07936487 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 9, 2018First study: phase 1 study in Neovascular Age-related Macular DegenerationFirst studyNCT03777254 · 12 enrolled · China
- Mar 1, 2021Phase 2 study in Diabetic RetinopathyNCT04782128 · 120 enrolled · China
- Jan 10, 2023Phase 3 study in Wet Age-related Macular DegenerationNCT05727397 · 432 planned · China
- May 19, 2023Phase 3 study in Diabetic Macular EdemaNCT05885503 · 316 planned · China
- Nov 8, 2026Phase 3 study in Diabetic Macular Edema (DME)NCT07936487 · 350 planned · China
Ahead
- Dec 1, 2028Primary completion: phase 3 study in Diabetic Macular Edema (DME)NCT07936487
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07936487Diabetic Macular Edema (DME) · China | 3 | Not yet recruiting | Dec 1, 2028 | 350 |
| NCT05885503Diabetic Macular Edema · China | 3 | Recruiting | Jun 2026 | 316 |
| NCT05727397Wet Age-related Macular Degeneration · China | 3 | Recruiting | Nov 29, 2025 | 432 |
| NCT04782128Diabetic Retinopathy · China | 2 | UNKNOWN | May 2024 | 120 |
| NCT03777254Neovascular Age-related Macular Degeneration · China | 1 | Completed | Aug 20, 2019 | 12 |
How it is read
Names in the registry
- “RC28-E”, 3 entries
- “RC28-E injection”, 1 entry
- “RC-28E”, 1 entry
Conditions, from the studies’ own filings
- Macular Edema, 2 studies
- Macular Degeneration, 2 studies
- Diabetic Retinopathy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.